Ciclosporin - Sigmoid Pharma

Drug Profile

Ciclosporin - Sigmoid Pharma

Alternative Names: AlloCol; Cyclosporin - Sigmoid Pharma; Cyclosporine - Sigmoid Pharma; Cyclosporine A - Sigmoid Pharma; CyCol; CyCron; CyLow; Oral cyclosporine - Sigmoid Pharma

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sigmoid Pharma
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes - Graft-versus-host disease; Transplant rejection; Ulcerative colitis

Highest Development Phases

  • Phase II Ulcerative colitis
  • No development reported Crohn's disease; Graft-versus-host disease; Psoriasis; Transplant rejection

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Crohn's-disease(In volunteers) in United Kingdom (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In volunteers) in United Kingdom (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top